vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Average Target Price of $55.83 According to Brokerages

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $55.83.

Several research firms have recently issued reports on VTVT. Zacks Research upgraded shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. BTIG Research raised their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. Finally, Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th.

vTv Therapeutics Trading Up 3.7%

Shares of VTVT opened at $31.18 on Wednesday. The business’s 50 day moving average is $32.02 and its 200 day moving average is $33.68. The company has a market capitalization of $122.85 million, a PE ratio of -29.42 and a beta of 0.21. vTv Therapeutics has a 12-month low of $19.50 and a 12-month high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Equities research analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.